Sun Pharmaceutical Industries Limited
SUNPHARMA
株式のランク
#532
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
株価
$19.19
時価総額
$46.05B
変化（1日）
-0.23%
変化（1年）
-0.07%
国
IN
取引 Sun Pharmaceutical Industries Limited (SUNPHARMA)
カテゴリー
Healthcare
Sun Pharmaceutical Industries Limited（SUNPHARMA）の収益
Jun 2026 時点の収益 TTM: $6.61B
Sun Pharmaceutical Industries Limited の最新の財務報告によると、現在の収益 (TTM) は $6.61B です。2024 年には $5.82B の収益があり、これは 2023 年の $5.34B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Sun Pharmaceutical Industries Limited の収益履歴（2004 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $6.61B | 7.55% |
| 2025 | $6.15B | 5.70% |
| 2024 | $5.82B | 8.91% |
| 2023 | $5.34B | 4.87% |
| 2022 | $5.09B | 11.28% |
| 2021 | $4.58B | 4.98% |
| 2020 | $4.36B | 4.14% |
| 2019 | $4.19B | 3.17% |
| 2018 | $4.06B | -15.97% |
| 2017 | $4.83B | 13.79% |
| 2016 | $4.24B | -3.35% |
| 2015 | $4.39B | 63.63% |
| 2014 | $2.68B | 29.00% |
| 2013 | $2.08B | 31.80% |
| 2012 | $1.58B | 22.91% |
| 2011 | $1.28B | 47.70% |
| 2010 | $869.23M | 3.29% |
| 2009 | $841.54M | 0.33% |
| 2008 | $838.79M | 70.54% |
| 2007 | $491.84M | 33.83% |
| 2006 | $367.50M | 33.92% |
| 2005 | $274.42M | 20.98% |
| 2004 | $226.82M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
